GlassScriptPhysician profile
Shane Jeffers
NPI 1053707893
$9,828.40
in general payments reported to CMS, 2019-2025
36 companies · $867 in 2025
The $867 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $240 · 2022: $1,249 · 2023: $3,942 · 2024: $3,531 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,319 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,318.90 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,278.78 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,109.03 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Gilead Sciences, INC. | $910.19 | 2023-2025 | Descovy, Epclusa |
| Novo Nordisk INC | $870.90 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $812.95 | 2023-2025 | |
| Glaxosmithkline, LLC. | $663.51 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $627.83 | 2022-2024 | Freestyle Libre 3 |
| Abbvie INC. | $527.43 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $361.89 | 2023-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $269.70 | 2023-2024 | Rexulti, Nuedexta |
| Exact Sciences Corporation | $253.61 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $249.40 | 2022-2024 | Veozah, Myrbetriq |
| Idorsia Pharmaceuticals US INC | $237.01 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.12 | 2022-2025 | Jardiance |
| Amgen INC. | $185.52 | 2022-2024 | Prolia, Evenity |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $157.94 | 2024 | Voquezna |
| Pfizer INC. | $141.58 | 2022-2025 | |
| Axsome Therapeutics, INC. | $136.36 | 2023-2024 | Auvelity |
| Alkermes, INC. | $135.42 | 2022-2024 | Vivitrol |
| Merck Sharp & Dohme LLC | $121.09 | 2023-2024 | Verquvo, Belsomra, Gardasil |
| Dexcom, INC. | $101.61 | 2022-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $70.11 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $68.09 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.56 | 2023-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $46.69 | 2023-2024 | Xarelto |
| Lundbeck LLC | $35.48 | 2023-2024 | Rexulti |
| Esperion Therapeutics, INC. | $34.63 | 2023-2024 | Nexletol |
| Sanofi Pasteur INC. | $27.20 | 2023-2024 | |
| Ironwood Pharmaceuticals, INC | $25.92 | 2022-2023 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.69 | 2024 | Xifaxan |
| Horizon Therapeutics Plc | $15.60 | 2022 | |
| Irhythm Technologies, INC. | $15.38 | 2024 | Zio Xt Patch, Zio Monitor |
| Renalytix Ai, INC. | $15.11 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $14.52 | 2022 | |
| Amarin Pharma, INC. | $14.46 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.09 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Jeffers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.